We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Strong Growth Forecasted for Women's Health Diagnostics

By LabMedica International staff writers
Posted on 28 Dec 2014
Print article
Key women's health diagnostics are showing strong growth worldwide, according to healthcare market researcher Kalorama Information (New York, NY, USA), including, among others, the sectors for digital mammography, lab-based fertility testing, and bone densitometry.

Each of these key diagnostic areas is showing growth greater than 4% and as high as 6%. The women's health arena, once limited to obstetrics and gynecology, now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. Kalorama's new report “Diagnostic Markets for Women's Health” analyzes current and potential world markets for key diagnostic tests: pregnancy and ovulation, bone density, prenatal screening, ultrasound, mammography, Pap smear, colposcopy, HPV, UTI, and other testing.

"The life expectancy of women is longer than for men and is climbing steadily due to advancements in medicine," said Joseph A. Constance, author of the report, "Diagnostics are playing an ever-increasing role." One example is the growth in the mammography systems marketplace, which will continue thanks in part to increased public awareness of breast cancer and the high efficiency and low dosage capability of advanced digital equipment.

Fertility testing is another growth sector as, for example, more than 7 million Americans, approximately 12% of the population in reproductive years, are estimated to be infertile. As more couples address fertility issues and are presented with different treatment options, the market, namely lab-based immunoassays, should be strong, with growth in the 4% to 5% range annually worldwide.

Bone densitometry is another example. A woman's risk of hip fracture is equal to her risk of breast, uterine, and ovarian cancer combined. Osteoporosis is estimated to affect 200 million women worldwide: about 10% of age 60; 20% of age 70; 40% of age 80; over 65% of women aged 90. The disease impacts approximately 75 million people in Europe, the US, and Japan. The rise of osteoporosis has propelled the need for early detection and pushed demand for bone densitometers, driving this market up.

Kalorama's report generally forecasts future market growth for diagnostic tests to 2018. It also reviews the nature and direction of research and trends, and gives insight into some of the issues facing the industry. The report provides market forecasts based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data are generated into multiple year forecasts for different product segments covered in the report.

The report profiles several key companies, including large known companies as well as smaller firms with market niches. These companies are involved in developing and marketing over-the-counter (OTC), point-of-care (POC) in vitro diagnostic (IVD) tests, and screening systems.

Related Links:

Kalorama Information
Diagnostic Markets for Women's Health, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.